Comparison of In vivo toxicity and anti-glatiramer acetate IgG antibody titers in rats Treated with glatiramer acetate (Copaxone) and follow-on glatiramer acetate (FOGA) products

被引：0
|
作者：
Konya, A. [1 ]
Timan, B. [2 ]
Ashkenazi, N. [2 ]
Bursztyn, D. [2 ]
Gyure, L. [1 ]
Vardi, M. [2 ]
Alexander, J. [3 ]
Loupe, P. [4 ]
Nock, S. [5 ]
机构：
[1] Teva Pharmaceut Ind Ltd, Debrecen, Hungary
[2] Teva Pharmaceut Ind Ltd, Netanya, Israel
[3] Teva Pharmaceut Ind Ltd, Denver, CO USA
[4] Teva Pharmaceut Ind Ltd, Overland Pk, KS USA
[5] Teva Pharmaceut Ind Ltd, Redwood City, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P678
引用
收藏
页码：337 / 337
页数：1
相关论文
共 43 条
  • [1] Anti-glatiramer acetate antibody levels in treated multiple sclerosis patients
    Oger, J
    Gibb, E
    Basile, E
    Aziz, T
    MULTIPLE SCLEROSIS, 2005, 11 (01): : 119 - 119
  • [2] Genomic profiling and in vivo rat toxicity characterization of Copaxone and the Synthon European follow-on glatiramer acetate product
    Kolitz, S.
    Ashkenazi, N.
    Timan, B.
    Zhang, J.
    Funt, J.
    Beriozkin, O.
    Konya, A.
    Alexander, J.
    Loupe, P.
    Vardi, M.
    Weinstein, V.
    Melamed-Gal, S.
    Grossman, I.
    Zeskind, B.
    Nock, S.
    Hayden, M.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 940 - 941
  • [3] Physicochemical and biological characterization of the European follow-on glatiramer acetate product as compared to copaxone
    Timan, B.
    Komlosh, A.
    Beriozkin, O.
    Konya, A.
    Wells-Knecht, K.
    Weinstein, V.
    Sahly, Y.
    Gilbert, A.
    Melamed-Gal, S.
    Loupe, P.
    Grossman, I.
    Laufer, R.
    Hayden, M. R.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 869 - 870
  • [4] Physicochemical and Biological Characterization of both Copaxone and the European Follow-On Glatiramer Acetate Product
    Timan, Bracha
    Komlosh, Arthur
    Beriozkin, Olga
    Konya, Attila
    Wells-Knecht, Kevin
    Weinstein, Vera
    Sahly, Yousif
    Gilbert, Adrian
    Bar-Ilan, Oren
    Zhang, Jenny
    Funt, Jason
    Hasson, Tal
    Laifenfeld, Daphne
    Kolitz, Sarah
    Zeskind, Benjamin
    Melamed-Gal, Sigal
    Loupe, Pippa
    Grossman, Iris
    Laufer, Ralph
    Hayden, Michael
    NEUROLOGY, 2018, 90
  • [5] Long-term treatment of multiple sclerosis patients with glatiramer acetate: clinical efficacy and anti-glatiramer acetate antibodies profile
    Teitelbaum, D.
    Brenner, T.
    Abramsky, O.
    Sicsic, C.
    Arnon, R.
    Karussis, D.
    MULTIPLE SCLEROSIS, 2006, 12 : S98 - S99
  • [6] Comparison of Copaxone® and Synthon's therapeutically equivalent glatiramer acetate
    Arends, R. J.
    Wang, D.
    Buurman, M.
    Luten, J.
    Koper, N. P.
    Wolf, C.
    Scheren, M.
    PHARMAZIE, 2019, 74 (08): : 449 - 461
  • [7] Long Term Treatment of Multiple Sclerosis with Glatiramer Acetate: Natural History of the Subtypes of Anti-Glatiramer Acetate Antibodies and Their Correlation with Clinical Efficacy
    Brenner, Talma
    Teitelbaum, Dvora
    Sicsic, Camille
    Karussis, Dimitrios
    NEUROLOGY, 2010, 74 (09) : A423 - A423
  • [8] Long-term treatment of multiple sclerosis with glatiramer acetate: Natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy
    Karussis, Dimitros
    Teitelbaum, Dvora
    Sicsic, Camille
    Brenner, Talma
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 220 (1-2) : 125 - 130
  • [9] Characterization and Comparison of the Gene Expression Profiles of Copaxone® and Mylan Glatiramer Acetate
    Smith, Jeffrey
    Hsu, Chun-Nan
    Lipsky, Peter
    NEUROLOGY, 2018, 90
  • [10] Anti-glatiramer acetate antibodies profile in long-term treated multiple sclerosis patients
    Brenner, T.
    Karusis, D.
    Abramsky, O.
    Sicsic, C.
    Arnon, R.
    Teitelbaum, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 28 - 28
12345